Haleon plc 6-K, filed Nov 2, 2026
Haleon plc (HLN)
6-K
2026-11-02
For: 2026-11-02
View Original
Added on
November 02, 2026
About this 6-K
Haleon plc filed this 6-K on November 2, 2026.
Haleon disclosed that Bláthnaid Bergin purchased 7,670 ordinary shares at £3.242 per share on 30 October 2026 through the London Stock Exchange. AI summary
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the month of November 2026
Commission File Number: 001-41411
Haleon plc
(Translation
of registrant’s name into English)
Building 5, First Floor, The Heights,
Weybridge, Surrey, KT13 0NY
(Address
of principal executive offices)
Indicate
by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F:
|
|
Form
20-F ☒
|
Form
40-F ☐
|
|
EXHIBIT INDEX
|
Exhibit
Number
|
Description
|
|
99.1
|
02
November 2026 - “Director/PDMR
Shareholding”
|
99.1
Haleon plc: Director/PDMR
Shareholding
02
November 2026: Haleon plc (the
“Company” or “Haleon”) (LSE/NYSE:HLN) today
announces notification and public disclosure in accordance with the
requirements of The UK Market Abuse Regulation of Transactions by
Persons Discharging Managerial Responsibilities
("PDMRs").
On 30 October 2026, the Company received notification of the
following transaction as detailed below.
|
1
|
Details of the issuer, emission allowance market
participant
|
||||
|
a)
|
Name
|
Haleon plc
|
|||
|
b)
|
LEI
|
549300PSB3WWEODCUP19
|
|||
|
2
|
Reason for the notification
|
||||
|
a)
|
Position/status
|
Independent Non-Executive Director
|
|||
|
b)
|
Initial notification /Amendment
|
Initial Notification
|
|||
|
3
|
Details of the person discharging managerial responsibilities /
person closely associated (“PCA”)
|
||||
|
a)
|
PDMR/PCA
|
PDMR
|
|||
|
b)
|
Name
|
Bláthnaid Bergin
|
|||
|
4
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transactions have been
conducted
|
||||
|
a)
|
Description of Instrument
Identification code
|
Share
GB00BMX86B70
|
|||
|
b)
|
Nature of the transaction
|
Purchase of Ordinary Shares in the Company
|
|||
|
c)
|
Currency, Price(s) and volume(s)
|
|
|
|
|
|
|
|
Price(s)
|
Volume(s)
|
|
|
|
|
|
£3.242
|
7,670
|
|
|
|
|
|
|
|
|
|
|
d)
|
Aggregated information
|
N/A - single transaction
|
|||
|
|
|
||||
|
- Aggregated volume
|
|
||||
|
|
|
||||
|
- Price
|
|
||||
|
|
|
||||
|
e)
|
Date of the transaction
|
30 October 2026
|
|||
|
f)
|
Place of the transaction
|
London Stock Exchange (XLON)
|
|||
Amanda Mellor
Company Secretary
About Haleon
Haleon (LSE/NYSE: HLN) is a consumer company that is solely focused
on better everyday health. Our people, our brands, our research,
our investment and our innovation are aimed at improving the
everyday health of consumers. Our product portfolio spans six major
categories - Oral Health, Vitamins, Minerals and Supplements (VMS),
Pain Relief, Respiratory Health, Digestive Health and Therapeutic
Skin Health and Other. Our superior brands - such as
Advil, Centrum, Otrivin, Panadol, parodontax, Polident, Sensodyne, Theraflu and Voltaren – are trusted by more than one billion
consumers and are recommended by health professionals around the
world.
For more information, please visit www.haleon.com.
SIGNATURE
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorized.
|
|
|
HALEON PLC
(Registrant)
|
|
|
Date:
November 02, 2026
|
By:
|
/s/
Amanda Mellor
|
|
|
|
|
Name:
|
Amanda
Mellor
|
|
|
|
Title:
|
Company
Secretary
|